CN107213138A - Time-releasable medications treat the method and pharmaceutical composition of hypertension - Google Patents
Time-releasable medications treat the method and pharmaceutical composition of hypertension Download PDFInfo
- Publication number
- CN107213138A CN107213138A CN201710664741.3A CN201710664741A CN107213138A CN 107213138 A CN107213138 A CN 107213138A CN 201710664741 A CN201710664741 A CN 201710664741A CN 107213138 A CN107213138 A CN 107213138A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- pellets
- release phase
- dissolution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 201
- 229940079593 drug Drugs 0.000 title claims abstract description 157
- 238000000034 method Methods 0.000 title claims abstract description 92
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 80
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 42
- 238000002483 medication Methods 0.000 title abstract 4
- 238000000576 coating method Methods 0.000 claims abstract description 65
- 239000003085 diluting agent Substances 0.000 claims abstract description 58
- 230000001070 adhesive effect Effects 0.000 claims abstract description 53
- 239000000853 adhesive Substances 0.000 claims abstract description 50
- 239000007884 disintegrant Substances 0.000 claims abstract description 37
- 230000001105 regulatory effect Effects 0.000 claims abstract description 5
- 239000008188 pellet Substances 0.000 claims description 215
- 239000012738 dissolution medium Substances 0.000 claims description 75
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 68
- 238000001035 drying Methods 0.000 claims description 65
- 239000011248 coating agent Substances 0.000 claims description 62
- 239000011230 binding agent Substances 0.000 claims description 57
- 238000004090 dissolution Methods 0.000 claims description 52
- 239000000463 material Substances 0.000 claims description 42
- 238000002156 mixing Methods 0.000 claims description 40
- 229920002472 Starch Polymers 0.000 claims description 39
- 238000002360 preparation method Methods 0.000 claims description 39
- 239000008107 starch Substances 0.000 claims description 39
- 235000019698 starch Nutrition 0.000 claims description 39
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 38
- 238000005563 spheronization Methods 0.000 claims description 38
- 229960004699 valsartan Drugs 0.000 claims description 38
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 38
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 37
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 31
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 31
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 31
- 230000036772 blood pressure Effects 0.000 claims description 30
- 239000011247 coating layer Substances 0.000 claims description 30
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 26
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 26
- 229940069328 povidone Drugs 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 239000007902 hard capsule Substances 0.000 claims description 21
- 239000007779 soft material Substances 0.000 claims description 20
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 19
- 229960000830 captopril Drugs 0.000 claims description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 229960003943 hypromellose Drugs 0.000 claims description 18
- 239000002775 capsule Substances 0.000 claims description 15
- 238000007922 dissolution test Methods 0.000 claims description 15
- 229920000178 Acrylic resin Polymers 0.000 claims description 14
- 239000004925 Acrylic resin Substances 0.000 claims description 14
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 14
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 14
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 14
- 239000011734 sodium Substances 0.000 claims description 14
- 229910052708 sodium Inorganic materials 0.000 claims description 14
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 229920001353 Dextrin Polymers 0.000 claims description 11
- 239000004375 Dextrin Substances 0.000 claims description 11
- 229960000528 amlodipine Drugs 0.000 claims description 11
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 11
- 229960000913 crospovidone Drugs 0.000 claims description 11
- 235000019425 dextrin Nutrition 0.000 claims description 11
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 11
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 239000002002 slurry Substances 0.000 claims description 10
- 239000002220 antihypertensive agent Substances 0.000 claims description 8
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 8
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 8
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 8
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- 239000001856 Ethyl cellulose Substances 0.000 claims description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 6
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 6
- 229920001249 ethyl cellulose Polymers 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 210000004211 gastric acid Anatomy 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 6
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 235000010981 methylcellulose Nutrition 0.000 claims description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 6
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 6
- 235000010413 sodium alginate Nutrition 0.000 claims description 6
- 239000000661 sodium alginate Substances 0.000 claims description 6
- 229940005550 sodium alginate Drugs 0.000 claims description 6
- 229940032147 starch Drugs 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 5
- 230000001631 hypertensive effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 4
- 229920003148 Eudragit® E polymer Polymers 0.000 claims description 4
- 229920003136 Eudragit® L polymer Polymers 0.000 claims description 4
- 229920003137 Eudragit® S polymer Polymers 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 claims description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- 238000002835 absorbance Methods 0.000 claims description 3
- 239000012790 adhesive layer Substances 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 229940009098 aspartate Drugs 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 3
- 238000011978 dissolution method Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 3
- 239000013558 reference substance Substances 0.000 claims description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 238000002651 drug therapy Methods 0.000 claims description 2
- 238000005243 fluidization Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 46
- 239000006187 pill Substances 0.000 description 36
- 239000011812 mixed powder Substances 0.000 description 27
- 230000000694 effects Effects 0.000 description 22
- 238000005520 cutting process Methods 0.000 description 18
- 238000001125 extrusion Methods 0.000 description 18
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 17
- 238000013265 extended release Methods 0.000 description 12
- 230000003111 delayed effect Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 9
- 230000002051 biphasic effect Effects 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 229940127088 antihypertensive drug Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002618 waking effect Effects 0.000 description 6
- 102000005862 Angiotensin II Human genes 0.000 description 5
- 101800000733 Angiotensin-2 Proteins 0.000 description 5
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 5
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 5
- 229960004005 amlodipine besylate Drugs 0.000 description 5
- 229950006323 angiotensin ii Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 230000007211 cardiovascular event Effects 0.000 description 4
- 230000007213 cerebrovascular event Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000007939 sustained release tablet Substances 0.000 description 4
- 101150059573 AGTR1 gene Proteins 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- -1 [2'- (1H-tetrazole-5-yl) [1,1' -biphenyl]-4-yl]Methyl Chemical group 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229960001597 nifedipine Drugs 0.000 description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001020 rhythmical effect Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 208000007718 Stable Angina Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- HTIQEAQVCYTUBX-KRWDZBQOSA-N (S)-amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-KRWDZBQOSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 101150116411 AGTR2 gene Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 238000011616 hypertension animal model Methods 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229950008554 levamlodipine Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to the method and pharmaceutical composition that time-releasable medications treat hypertension.Specifically, the present invention relates to a kind of pharmaceutical composition that hypertension is treated for time-releasable medications, the pharmaceutical composition is in the form of piller, including the first release mutually part and the second release phase part, wherein the piller of the first release phase part includes：Active medicine, diluent, disintegrant, adhesive and optional coatings；The piller of second release phase part includes：Active medicine, diluent, disintegrant, adhesive and the coatings of regulating drug release.The pharmaceutical composition used in the method and this method of time-releasable medications treatment hypertension of the present invention is a kind of excellent tool of clinically hypertension chronotherapeutics.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly belongs to the technical field of preparations for treating hypertension by releasing medicines at regular time. In particular, the present invention relates to a method for treating hypertension with a time-release drug, and a pharmaceutical composition for use in the method for treating hypertension with the time-release drug. The method for treating hypertension by using the time release medicine and the pharmaceutical composition used in the method are an excellent tool for clinical time treatment of hypertension. The antihypertensive drug of the present invention is, for example, valsartan, amlodipine and pharmaceutically acceptable salts thereof, captopril and the like.
Background
The blood pressure of a human body shows rhythmic changes within 24 hours: blood pressure rapidly rises to a peak value within hours after waking in the early morning, and falls to a valley value in the middle-night to early morning. The morning peak phenomenon is one of two important features of blood pressure.
According to the research results of chronopharmacology in recent years, the heart rate and blood pressure of a person are in a low trough at night, so that the attack rate of angina and hypertension at the time is low, at the time, the medicine is basically not required to be provided in blood, and the heart rate and blood pressure of the person are increased within a few hours after waking in the morning, so that angina and hypertension are frequently generated at the time, and at the time, if a certain blood concentration peak value can be synchronously maintained in the blood, the attack of cardiovascular diseases can be effectively prevented and reduced.
Blood pressure is regulated by various factors in nerve body fluid, the activity of a sympathetic nervous system, the levels of renin, angiotensin II, aldosterone and the like are also changed rhythmically, and the activity of the substances is obviously increased in the early morning to be the main reason of morning peak phenomenon of blood pressure. Consistent with this, many clinical studies and meta-analyses have shown that cardiovascular and cerebrovascular events such as myocardial infarction, myocardial ischemia, sudden death, and stroke are all well in the early morning.
Understanding the rhythmic change rule of blood pressure and the relationship between the rhythmic change rule and cardiovascular and cerebrovascular events has important guiding significance for treating hypertension clinically. The ideal antihypertensive drug has good compliance, and can stably reduce blood pressure within 24 hours, remarkably reduce early blood pressure of patients, and ensure that the patients with hypertension safely pass the high-incidence period of cardiovascular and cerebrovascular events; can recover the normal blood pressure mode of the patient, reduce the blood pressure variability and effectively protect the functions of target organs. This is the "chronotherapy" of hypertension.
"chronotherapy" is a newer therapeutic concept. The time therapeutics aims at the time biological characteristics of human bodies, selects proper pharmaceutical preparations and reasonable administration time or a specific administration technology to ensure that the pharmaceutical action is consistent with the rhythm of diseases, thereby achieving the purposes of optimizing the treatment effect and reducing the adverse drug reactions. At present, researchers at home and abroad are actively developing antihypertensive drugs according to the time therapeutic principle of hypertension.
As for general preparations of captopril and other medicines, the captopril does not act through liver metabolism, is metabolized fast in vivo, takes effect within 15-30 minutes after oral administration, has a half-life period of about 2 hours, has a duration of only 4-8 hours, and can achieve a good blood pressure reduction effect only after being taken for a plurality of times in 1 day. At present, the captopril sustained release tablet is reported in research reports, such as the captopril sustained release tablet reported in the research on the three-dimensional dissolution characteristics and in-vivo and in-vitro correlation of the captopril sustained release tablet, which is compiled in the proceedings of the academy of Guangdong institute of medicine, 1997, 13(2), 73-74, Linhuaqing and the like, and aims to prolong the half-life period and reduce the medicine taking times of patients, but the delayed release of the captopril sustained release tablet cannot be controlled. At present, no captopril controlled release preparation capable of delaying release exists, which aims at the morning peak phenomenon; the current conventional captopril preparation is difficult to enable a hypertensive patient to avoid the dangerous early morning time, and the inconvenience of getting up to take the medicine in the early morning is brought to the life of the patient. Therefore, it is necessary to design a captopril controlled release preparation which is taken before sleep (9-11: 00 pm), and 3: 00 effective dose of medicine is released continuously, so that the action of the medicine is consistent with the rhythm of disease occurrence, and the hypertensive can safely pass the high-incidence period of the cardiovascular and cerebrovascular events. Thus, the dosage form is designed to delay release for 4-6 hours, preferably 5 hours, and then continue release for a period of time to delay the time of drug release and increase the duration of drug release.
The requirements also exist for other medicines, namely the medicines are not taken usually in the period from the time when the medicines are taken before sleep at night (9: 00-10: 00 evening) to the time when the medicines get up in the next morning, but the medicines are not taken in the period from 3: 00-4: the morning wake at around 00 hours is the period during which a booster dose is required. Therefore, it is important to provide a method for treating hypertension by releasing drugs with two drug-releasing phases at regular time from the late time to the early morning, for example, a part of the drugs is released in gastric juice within 1-2 hours after the drugs are taken, and then another part of the drugs is released under intestinal juice condition within 6-7 hours after the drugs are taken, so as to meet the requirement of drug administration in two time periods, which is still desired by the skilled person.
Disclosure of Invention
The invention aims to provide a method for treating hypertension by using a time release medicine and a pharmaceutical composition for the method for treating hypertension by using the time release medicine. The method for treating hypertension by timed release of a drug and the pharmaceutical composition used in the method of the present invention are expected to be excellent tools for chronotherapy of hypertension in clinical practice. Antihypertensive drugs such as valsartan, amlodipine and pharmaceutically acceptable salts thereof, captopril and the like which are involved in the method of treating hypertension according to the present invention.
To this end, the present invention provides in a first aspect a pharmaceutical composition for timed release drug therapy of hypertension, the pharmaceutical composition being in the form of pellets comprising a first release phase section and a second release phase section; wherein,
the pellets of the first release phase portion comprise: an active drug, a diluent, a disintegrant, a binder, and optionally a coating layer;
the pellets of the second release phase portion comprise: active drug, diluent, disintegrating agent, adhesive and coating layer for regulating drug release.
The pharmaceutical composition according to any embodiment of the first aspect of the invention, wherein the active drug is a blood pressure lowering drug.
The pharmaceutical composition according to any embodiment of the first aspect of the invention, wherein the active drug is a blood pressure lowering agent selected from the group consisting of: valsartan, amlodipine and pharmaceutically acceptable salts thereof such as maleate, besylate, aspartate, mesylate, captopril and the like.
The pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the active drug in the first release phase portion accounts for 30% to 50% of the total amount of the active drug in the pharmaceutical composition, and the active drug in the second release phase portion accounts for 50% to 70% of the total amount of the active drug in the pharmaceutical composition.
The pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the diluent in the first release phase part is selected from the group consisting of: microcrystalline cellulose, starch, dextrin, lactose, dibasic calcium phosphate, and combinations thereof.
The pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the diluent is present in the first release phase part in an amount of 30 to 80 parts by weight, for example 30 to 60 parts by weight, per 30 parts by weight of the active agent.
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the disintegrant in the first release phase portion is selected from the group consisting of: crospovidone, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, croscarmellose sodium, and combinations thereof.
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the weight of the disintegrant in the first release phase part is 5 to 30 parts by weight, for example 10 to 20 parts by weight, per 30 parts by weight of the active drug.
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the binder in the first release phase part is selected from the group consisting of: povidone, methylcellulose, ethylcellulose, carboxymethylcellulose, starch slurry, hypromellose, gelatin, polyethylene glycol, sodium alginate, water, ethanol, and combinations thereof. In one embodiment, the binder is selected from the group consisting of povidone, starch slurry, hypromellose, water, and combinations thereof. In one embodiment, the binder is selected from povidone, hypromellose, which is used in water formulated into binder solutions (such binder solutions typically used in the art have a concentration of typically 3-8%).
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the binder is present in the first release phase part in an amount of 2 to 10 parts by weight, for example 3 to 8 parts by weight, per 30 parts by weight of the active agent.
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the coating layer of the first release phase part is a coating layer capable of dissolving in the gastric acid environment. Examples of specific coating materials are Eudragit E, hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), and the like.
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the weight of the coating layer in the first release phase part is 10 to 30 parts by weight, for example 15 to 25 parts by weight, per 30 parts by weight of the active drug.
The pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the pellets of the first release phase fraction have an average diameter of 0.2 to 2mm, such as 0.5 to 1.5mm, such as 0.5 to 1.2mm, such as 0.5 to 0.8 mm.
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the pellets of the first release phase fraction are eluted in four dissolution media at 30min in an amount of more than 80% of the content of the main drug in the pellets, as determined by dissolution test a below;
the procedure for the dissolution test method A is as follows: filling an appropriate amount of pellets corresponding to 50mg of an active drug (such as valsartan) into an empty capsule, respectively using a pH1.2 hydrochloric acid solution, a pH4.0 phosphate buffer (6.80 g of potassium dihydrogen phosphate is taken and dissolved in water to 1000mL, and the pH value is adjusted to 4.0 by phosphoric acid or sodium hydroxide) and a pH6.8 phosphate buffer (6.80 g of potassium dihydrogen phosphate and 0.90g of sodium hydroxide are taken and dissolved in water to 1000mL, the pH value is adjusted to 6.8), 1000mL of water is taken as a dissolution medium, the rotating speed is 100 revolutions per minute, operating according to the method, taking an appropriate amount of the solution at a specified time point, filtering, precisely taking an appropriate amount of a subsequent filtrate, quantitatively diluting the subsequent filtrate with the dissolution medium to prepare a solution containing about 16 mu g of the active drug in each 1mL, and measuring absorbance at a wavelength of 250nm according to an ultraviolet-visible spectrophotometry according to the first method of the general rule of the national regulation of "Chinese pharmacopoeia" 2015 edition; taking another appropriate amount of active drug reference substance, precisely weighing, adding dissolution medium to dissolve and quantitatively diluting to obtain solution containing 16 μ g per 1ml, measuring by the same method, and calculating dissolution amount of each capsule in different dissolution media.
It is essential that the pellets of the first release phase fraction of the present invention release the drug rapidly, which is a fraction of the drug that is effective rapidly after the formulation is taken, to produce the therapeutic effect of the conventional hypotensive drugs.
The pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the diluent in the second release phase portion is selected from the group consisting of: microcrystalline cellulose, starch, dextrin, lactose, dibasic calcium phosphate, and combinations thereof.
The pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the diluent is present in the second release phase part in an amount of 30 to 80 parts by weight, for example 30 to 60 parts by weight, per 50 parts by weight of the active agent.
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the disintegrant in the second release phase portion is selected from the group consisting of: crospovidone, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, croscarmellose sodium, and combinations thereof.
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the weight of the disintegrant in the second release phase part is 5 to 30 parts by weight, for example 10 to 20 parts by weight, per 50 parts by weight of the active drug.
The pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the binder in the second release phase part is selected from the group consisting of: povidone, methylcellulose, ethylcellulose, carboxymethylcellulose, starch slurry, hypromellose, gelatin, polyethylene glycol, sodium alginate, water, ethanol, and combinations thereof. In one embodiment, the binder is selected from the group consisting of povidone, starch slurry, hypromellose, water, and combinations thereof. In one embodiment, the binder is selected from povidone, hypromellose, which is used in water formulated into binder solutions (such binder solutions typically used in the art have a concentration of typically 3-8%).
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the binder is present in the second release phase part in an amount of 2 to 10 parts by weight, for example 3 to 8 parts by weight, per 50 parts by weight of the active agent.
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the coating layer of the second release phase part is a coating layer that is insoluble in the gastric acid environment. For example, the coating material used for the coating layer is a gastric-soluble type coating material. Examples of typical coating materials are e.g. cellulose acetate phthalate, hypromellose phthalate (HPMCP), polyvinyl alcohol phthalate (PVAP), Eudragit L, Eudragit S, acrylic resin I, acrylic resin II, acrylic resin IV, methacrylic acid copolymers, etc.
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the weight of the coating layer in the second release phase part is 20 to 50 parts by weight, for example 20 to 40 parts by weight, per 50 parts by weight of the active drug.
The pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the pellets of the second release phase fraction have an average diameter of 0.2 to 2mm, such as 0.5 to 1.5mm, such as 0.5 to 1.2mm, such as 0.5 to 0.8 mm.
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the pellets of the second release phase fraction are taken in appropriate amounts at2 hours, 3 hours, 4 hours respectively upon dissolution in four dissolution media as determined by dissolution method a, for determining the amount of dissolution at that point in time in each dissolution media, wherein:
the dissolution amount in two dissolution media of pH1.2 and pH4.0 at 4 hr is less than 10% of the main drug content in the pellet;
the dissolution amount in two dissolution media of pH6.8 and water at2 hours is less than 15% of the content of the main drug in the pellet;
the dissolution amount in two dissolution media of pH6.8 and water at 3 hours is more than 80% of the content of the main drug in the pellet.
The pellets of the second release phase fraction of the present invention release substantially no drug in a medium of low pH within 4 hours, only very small amounts within 2 hours in a neutral medium but are able to release the majority of the drug at 3 hours. Thus, the pellets of the second release phase part are not released when the drug passes through the stomach after administration (usually, 2 hours), only a tiny amount of the drug is released within 2 hours after entering the intestinal tract after 2 hours, and most of the drug can be released in about 3 hours in the intestinal tract, that is, the pellets of the second release phase part are mostly released after 5 hours after administration, and in the case of administration before bedtime (9: 00-10: 00 pm) in the usual evening, the drug in the pellets of the second release phase part is mostly released after 5 hours, so that 3: 00-4: the drug is absorbed into the blood before the arrival of about 00 morning waking hours to control the blood pressure rise of the morning waking hours.
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the amount of dissolution in each dissolution medium at that time point is determined by taking appropriate amounts of solutions at 0.5 hour, 2 hours, 3 hours, 4 hours, respectively, upon dissolution in four dissolution media, as determined by dissolution assay a, wherein:
the amount eluted at 0.5 hours in both dissolution media pH1.2 and pH4.0 is 90-120% (e.g. 90-110%) of the amount of drug in the first release phase portion of the pharmaceutical composition;
the amount eluted at 4 hours in both dissolution media pH1.2 and pH4.0 is 100-140% (e.g., 100-125%) of the amount of drug in the first release phase portion of the pharmaceutical composition;
the amount eluted at2 hours in both dissolution media pH6.8 and water is 100-140% (e.g. 100-130%) of the amount of drug in the first release phase portion of the pharmaceutical composition;
the amount of the extract in the two dissolution media of pH6.8 and water at 3 hr is more than 85% (such as more than 90%) of the amount of the Chinese medicinal materials in the pharmaceutical composition.
Thus, the pharmaceutical composition provided by the invention has two release stages in the whole gastrointestinal tract, wherein the first release stage can release a first part of drug but not release a second part of drug basically in the gastric juice, the medicament still does not release the drug basically between 2 hours after entering the intestinal tract, and more than 85% of the total dosage of the medicament can be released after about 3 hours, thereby providing the possibility of reducing the pressure by taking the medicament regularly at night and reducing the pressure by waking at morning. It has been surprisingly found that when a small amount of liquid paraffin as a coating aid (e.g. added in an amount of 1-3% by weight of the coating material, e.g. 2%) is added to the coating solution when coating the pellets of the second release phase fraction, the pellets of the second release phase fraction are capable of eluting less than 15% of the main drug content in the pellets within 2 hours and more than 80% of the main drug content in the pellets within 3 hours in both neutral dissolution media, ph6.8 and water. If this coating aid is not added, the resulting pellets of the second release phase fraction will mostly dissolve at1 hour in both neutral dissolution media ph6.8 and water. Therefore, in one embodiment of the present invention, the coating auxiliary agent is further included in the coating layer of the second phase-releasing part in an amount of 5 to 10% by weight of the coating material in the coating layer.
Further, the second aspect of the present invention provides a method for treating hypertension by timed release of a drug, which comprises administering to a hypertensive patient in need thereof a therapeutically effective amount of a pharmaceutical composition in the form of pellets comprising a first release phase part and a second release phase part before bedtime evening (which may be typically 9: 00-10: 00 evening); wherein,
the pellets of the first release phase portion comprise: an active drug, a diluent, a disintegrant, a binder, and optionally a coating layer;
the pellets of the second release phase portion comprise: active drug, diluent, disintegrating agent, adhesive and coating layer for regulating drug release.
Alternatively, or in other words, the second aspect of the invention provides the use of the pharmaceutical composition, for example of any of the embodiments of any of the aspects of the invention, in the manufacture of a medicament for the timed release drug treatment of hypertension. For example, the timed release medicament for treating hypertension is to administer a therapeutically effective amount of the pharmaceutical composition to a hypertensive patient in need thereof before going to sleep at night (usually, 9: 00-10: 00 at night).
The method according to any embodiment of the second aspect of the invention, wherein the active drug is a blood pressure lowering drug.
The method according to any of the embodiments of the second aspect of the invention, wherein the active drug is a blood pressure lowering drug selected from the group consisting of: valsartan, amlodipine and pharmaceutically acceptable salts thereof such as maleate, besylate, aspartate, mesylate, captopril and the like.
The method according to any embodiment of the second aspect of the present invention, wherein the active drug in the first release phase fraction accounts for 30% to 50% of the total amount of active drug in the pharmaceutical composition, and the active drug in the second release phase fraction accounts for 50% to 70% of the total amount of active drug in the pharmaceutical composition.
The method according to any one of the embodiments of the second aspect of the present invention, wherein the diluent in the first release phase portion is selected from the group consisting of: microcrystalline cellulose, starch, dextrin, lactose, dibasic calcium phosphate, and combinations thereof.
The process according to any embodiment of the second aspect of the present invention, wherein the weight of the diluent in the first release phase part is 30 to 80 parts by weight, for example 30 to 60 parts by weight, per 30 parts by weight of the active drug.
The method according to any one of the embodiments of the second aspect of the present invention, wherein the disintegrant in the first release phase portion is selected from the group consisting of: crospovidone, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, croscarmellose sodium, and combinations thereof.
The process according to any embodiment of the second aspect of the present invention, wherein the weight of the disintegrant in the first release phase fraction is 5 to 30 parts by weight, for example 10 to 20 parts by weight, per 30 parts by weight of active drug.
The method according to any one of the embodiments of the second aspect of the present invention, wherein the binder in the first release phase part is selected from the group consisting of: povidone, methylcellulose, ethylcellulose, carboxymethylcellulose, starch slurry, hypromellose, gelatin, polyethylene glycol, sodium alginate, water, ethanol, and combinations thereof. In one embodiment, the binder is selected from the group consisting of povidone, starch slurry, hypromellose, water, and combinations thereof. In one embodiment, the binder is selected from povidone, hypromellose, which is used in water formulated into binder solutions (such binder solutions typically used in the art have a concentration of typically 3-8%).
The method according to any embodiment of the second aspect of the present invention, wherein the binder is present in the first release phase fraction in an amount of 2 to 10 parts by weight, such as 3 to 8 parts by weight, per 30 parts by weight of active drug.
The method according to any embodiment of the second aspect of the present invention, wherein the coating layer of the first release phase part is a coating layer capable of dissolving in the gastric acid environment. Examples of specific coating materials are Eudragit E, hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), and the like.
The process according to any embodiment of the second aspect of the present invention, wherein the weight of the coating layer in the first release phase fraction is 10 to 30 parts by weight, such as 15 to 25 parts by weight, per 30 parts by weight of active drug.
The process according to any embodiment of the second aspect of the present invention, wherein the pellets of the first release phase fraction have an average diameter of 0.2 to 2mm, such as 0.5 to 1.5mm, such as 0.5 to 1.2mm, such as 0.5 to 0.8 mm.
The method according to any of the embodiments of the second aspect of the present invention, wherein the pellets of the first release phase fraction are eluted in four dissolution media at 30min in an amount of more than 80% of the content of the main drug in the pellets, as determined by dissolution test a below;
the procedure for the dissolution test method A is as follows: filling an appropriate amount of pellets corresponding to 50mg of an active drug (such as valsartan) into an empty capsule, respectively using a pH1.2 hydrochloric acid solution, a pH4.0 phosphate buffer (6.80 g of potassium dihydrogen phosphate is taken and dissolved in water to 1000mL, and the pH value is adjusted to 4.0 by phosphoric acid or sodium hydroxide) and a pH6.8 phosphate buffer (6.80 g of potassium dihydrogen phosphate and 0.90g of sodium hydroxide are taken and dissolved in water to 1000mL, the pH value is adjusted to 6.8), 1000mL of water is taken as a dissolution medium, the rotating speed is 100 revolutions per minute, operating according to the method, taking an appropriate amount of the solution at a specified time point, filtering, precisely taking an appropriate amount of a subsequent filtrate, quantitatively diluting the subsequent filtrate with the dissolution medium to prepare a solution containing about 16 mu g of the active drug in each 1mL, and measuring absorbance at a wavelength of 250nm according to an ultraviolet-visible spectrophotometry according to the first method of the general rule of the national regulation of "Chinese pharmacopoeia" 2015 edition; taking another appropriate amount of active drug reference substance, precisely weighing, adding dissolution medium to dissolve and quantitatively diluting to obtain solution containing 16 μ g per 1ml, measuring by the same method, and calculating dissolution amount of each capsule in different dissolution media.
The method according to any one of the embodiments of the second aspect of the present invention, wherein the diluent in the second release phase portion is selected from the group consisting of: microcrystalline cellulose, starch, dextrin, lactose, dibasic calcium phosphate, and combinations thereof.
The process according to any embodiment of the second aspect of the present invention, wherein the weight of the diluent in the second release phase part is 30 to 80 parts by weight, for example 30 to 60 parts by weight, per 50 parts by weight of the active drug.
The method according to any one of the embodiments of the second aspect of the present invention, wherein the disintegrant in the first release phase portion is selected from the group consisting of: crospovidone, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, croscarmellose sodium, and combinations thereof.
The process according to any embodiment of the second aspect of the present invention, wherein the weight of the disintegrant in the second release phase fraction is 5 to 30 parts by weight, such as 10 to 20 parts by weight, per 50 parts by weight of active drug.
The method according to any one of the embodiments of the second aspect of the present invention, wherein the binder in the second release phase part is selected from the group consisting of: povidone, methylcellulose, ethylcellulose, carboxymethylcellulose, starch slurry, hypromellose, gelatin, polyethylene glycol, sodium alginate, water, ethanol, and combinations thereof. In one embodiment, the binder is selected from the group consisting of povidone, starch slurry, hypromellose, water, and combinations thereof. In one embodiment, the binder is selected from povidone, hypromellose, which is used in water formulated into binder solutions (such binder solutions typically used in the art have a concentration of typically 3-8%).
The method according to any embodiment of the second aspect of the present invention, wherein the binder is present in the second release phase fraction in an amount of 2 to 10 parts by weight, such as 3 to 8 parts by weight, per 50 parts by weight of active drug.
The method according to any of the embodiments of the second aspect of the present invention, wherein the coating layer of the second release phase part is a coating layer that is insoluble in the gastric acid environment. For example, the coating material used for the coating layer is a gastric-soluble type coating material. Examples of typical coating materials are e.g. cellulose acetate phthalate, hypromellose phthalate (HPMCP), polyvinyl alcohol phthalate (PVAP), Eudragit L, Eudragit S, acrylic resin I, acrylic resin II, acrylic resin IV, methacrylic acid copolymers, etc.
The process according to any embodiment of the second aspect of the present invention, wherein the weight of the coating layer in the second release phase fraction is 20 to 50 parts by weight, such as 20 to 40 parts by weight, per 50 parts by weight of the active drug.
The process according to any embodiment of the second aspect of the present invention, wherein the pellets of the second release phase fraction have an average diameter of 0.2 to 2mm, such as 0.5 to 1.5mm, such as 0.5 to 1.2mm, such as 0.5 to 0.8 mm.
The process according to any of the embodiments of the second aspect of the present invention, wherein the pellets of the second release phase fraction are taken in appropriate amounts at2 hours, 3 hours, 4 hours respectively upon dissolution in four dissolution media as determined by dissolution method a, the amount of dissolution at that time point in each dissolution media being determined, wherein:
the dissolution amount in two dissolution media of pH1.2 and pH4.0 at 4 hr is less than 10% of the main drug content in the pellet;
the dissolution amount in two dissolution media of pH6.8 and water at2 hours is less than 15% of the content of the main drug in the pellet;
the dissolution amount in two dissolution media of pH6.8 and water at 3 hours is more than 80% of the content of the main drug in the pellet.
According to the method of any embodiment of the second aspect of the present invention, the amount of the pharmaceutical composition eluted at the time point in each of the four dissolution media is determined by taking appropriate amounts of the solutions at 0.5 hour, 2 hours, 3 hours, and 4 hours, respectively, upon dissolution in the dissolution media as measured by dissolution assay method a, wherein:
the amount eluted at 0.5 hours in both dissolution media pH1.2 and pH4.0 is 90-120% (e.g. 90-110%) of the amount of drug in the first release phase portion of the pharmaceutical composition;
the amount eluted at 4 hours in both dissolution media pH1.2 and pH4.0 is 100-140% (e.g., 100-125%) of the amount of drug in the first release phase portion of the pharmaceutical composition;
the amount eluted at2 hours in both dissolution media pH6.8 and water is 100-140% (e.g. 100-130%) of the amount of drug in the first release phase portion of the pharmaceutical composition;
the amount of the extract in the two dissolution media of pH6.8 and water at 3 hr is more than 85% (such as more than 90%) of the amount of the Chinese medicinal materials in the pharmaceutical composition.
According to any of the embodiments of any of the aspects of the invention, wherein the pellets of the first release phase portion and the pellets of the second release phase portion of the pharmaceutical composition are each independently prepared according to a process comprising the steps of:
(1) adding the diluent and the disintegrant into the active medicine, uniformly mixing and crushing;
(2) preparing an adhesive solution with the concentration of 3-5% by using water, and preparing a soft material from the obtained material in the previous step;
(3) preparing pellets by extrusion-spheronization pelleting method or centrifugation-fluidization pelleting method, and drying to obtain pellet cores;
(4) coating the pellets of the second release phase fraction obtained in step (3), optionally with a coating of the pellets of the first release phase fraction;
(5) mixing the two pellets at a certain ratio, and filling into hollow capsule to obtain the pharmaceutical composition in the form of hard capsule preparation.
Any technical feature possessed by any one aspect of the invention or any embodiment of that aspect is equally applicable to any other embodiment or any embodiment of any other aspect, so long as they are not mutually inconsistent, although appropriate modifications to the respective features may be made as necessary when applicable to each other. Various aspects and features of the disclosure are described further below.
All documents cited herein are incorporated by reference in their entirety and to the extent such documents do not conform to the meaning of the present invention, the present invention shall control. Further, the various terms and phrases used herein have the ordinary meaning as is known to those skilled in the art, and even though such terms and phrases are intended to be described or explained in greater detail herein, reference is made to the term and phrase as being inconsistent with the known meaning and meaning as is accorded to such meaning throughout this disclosure. Various aspects of the invention are described further below.
The English name of valsartan is valsartan, N-valeryl-N- [ [2'- (1H-tetrazole-5-yl) [1,1' -biphenyl]-4-yl]Methyl radical]-L-valine of formula: c24H29N5O3The molecular weight of 435.52 is white crystal or white and white-like powder, has hygroscopicity, is extremely soluble in ethanol, is soluble in methanol, is slightly soluble in ethyl acetate and is almost insoluble in water, the valsartan is a non-peptide orally effective angiotensin II (AT) receptor antagonist, has high selectivity on a type I receptor (AT1), can competitively antagonize without any agonistic effect, can also inhibit the adrenal cells mediated by AT1 receptor from releasing aldosteron, but does not inhibit the release caused by potassium, thus showing the selective effect of the valsartan on AT1 receptors, the in vivo tests of various hypertension animal models show that the valsartan has good antihypertensive effect, has no obvious influence on the cardiocontractile function and the heart rate, does not produce the antihypertensive effect on normal blood pressure animals, is rapidly absorbed after oral administration, has the bioavailability of 23%, has the binding rate with plasma protein of 94% -97%, is discharged from 70% after the patient takes the blood pressure, 30% from kidney, shows the original shape, is about 7 hours, has the effect after the blood pressure is absorbed after the oral administration of β hours, and has the maximum effect after the blood pressure reduction after the blood pressure is reduced by one time of 366 hours and 366 hours.The hypotensive effect can last for 24 hours. The blood pressure reduction reaches the maximum effect 2-4 weeks after continuous medication. Can be used with hydrochlorothiazide, and has effect in lowering blood pressure. Valsartan is a non-precursor drug and has direct pharmacological activity without undergoing biotransformation by the liver. The oral administration has quick absorption, the absorption is influenced by eating, the bioavailability is 25 percent, and the binding rate with plasma protein is 95 percent. The medicine has quick effect and strong effect, the blood concentration reaches the peak value after 2 hours after the medicine is taken orally, and the effect lasts for more than 24 hours. The half-life period is 5-9 h, and the blood is discharged through biliary tract (70%) and kidney (30%). The valsartan is used for resisting hypertension and mild and moderate essential hypertension, and is particularly suitable for secondary hypertension caused by kidney damage. In general, valsartan is an angiotensin II receptor antagonist antihypertensive drug, and the drug has the effects of blocking angiotensin II type I (AT1) receptors, increasing angiotensin II plasma level, stimulating unblocked AT2 receptors and countering AT1 receptors, thereby achieving the effects of dilating blood vessels and reducing blood pressure. In the united states, valsartan is a drug used to treat hypertension, congestive heart failure, post-myocardial infarction. Valsartan, a product developed by Ciba-Geigy, Switzerland, acquired relative patent rights in the United states and Europe in 1995 and 1996, was first marketed in Germany in 7 months in 1996, and thereafter in Europe, the United states, Japan. Ciba-Geigy incorporated Nowa with Shande Shi in 1996. The valsartan has the characteristics of lasting and stable blood pressure reducing effect and small toxic and side effects.
Amlodipine, the english name Amlodipine, 6-methyl-2- (2-aminoethoxy) methyl-4- (2-chlorophenyl) -1, 4-dihydro-3, 5-pyridinedicarboxylic acid methylethyl ester, molecular formula: C20H25ClN2O5, molecular weight: 408.88. amlodipine is a nifedipine calcium antagonist. The effect of inhibiting calcium-induced aortic contraction is 2 times that of nifedipine. It is characterized by slow speed of binding and dissociation with receptors, so that the action of the drug is delayed and sustained for a long time. The selective effect on vascular smooth muscle is greater than that of nifedipine. It can increase cardiac output and coronary flow, increase myocardial oxygen supply, reduce oxygen consumption, and improve exercise ability for patients with myocardial ischemia. In addition, the product can activate LDL receptor, reduce accumulation of fat in artery wall and inhibit collagen synthesis, thus having anti-arteriosclerosis effect. The product has certain protective effect on kidney. The preparation comprises amlodipine besylate tablets, amlodipine mesylate tablets, levoamlodipine maleate tablets and the like. Amlodipine is suitable for treating mild and moderate hypertension, and has the curative effect similar to that of atenolol, captopril, diltiazem, nadolol, etc. Compared with verapamil, the antihypertensive drug has more continuous and stable antihypertensive effect and is used as a second-line drug for treating hypertension. The product can also be used for treating chronic stable angina (including patients with poor treatment effect on nitrate or beta-receptor blocking drugs), and can remarkably reduce angina attack frequency and prolong exercise time of patients. Amlodipine is clinically used for hypertension, and can be used alone or combined with other antihypertensive drugs; can also be used for chronic stable angina pectoris or vasospastic angina pectoris, and can be used alone or in combination with other antianginal drugs, such as nitrates and/or beta-blockers.
The method for treating hypertension by using the time release medicine and the pharmaceutical composition provided by the method have the excellent technical effects as described in the text.
Detailed Description
The present invention will be further described by the following examples, however, the scope of the present invention is not limited to the following examples. It will be understood by those skilled in the art that various changes and modifications may be made to the invention without departing from the spirit and scope of the invention. The present invention has been described generally and/or specifically with respect to materials used in testing and testing methods. Although many materials and methods of operation are known in the art for the purpose of carrying out the invention, the invention is nevertheless described herein in as detail as possible.
In the following specific examples section, the preparation of the formulation compositions is carried out, if not mentioned otherwise, in a dose of 100000 units of formulation or at least 5kg of material.
In the present invention, the pellets of the first release phase portion are rapidly released in vivo, and thus the pellets of this portion may also be referred to as immediate release pellets or immediate release pellets; for the same reason, the pellets of the second release phase fraction need to be delayed in vivo, and therefore the pellets of this fraction may also be referred to as delayed release pellets or extended release pellets or also as sustained release pellets or sustained release pellets.
Example 1 preparation of immediate Release pellets
The prescription proportion is as follows:
valsartan 30 parts by weight
Starch (diluent) 45 weight portions
15 parts by weight of sodium carboxymethyl starch (disintegrant)
5 parts of povidone (adhesive).
Preparation of pellets:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a 4% solution of the adhesive by using water as an adhesive solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. The pellets are moved into a drying room for drying, the drying condition is 30 +/-2 ℃, the drying time is 12 hours, and the dried pellets can be used as the quick-release pellets of the invention.
Example 2 preparation of immediate Release pellets
The prescription proportion is as follows:
valsartan 30 parts by weight
Dextrin (diluent) 30 weight portions
15 parts by weight of croscarmellose sodium (disintegrant)
And 8 parts of hydroxypropyl methylcellulose (adhesive).
Preparation of pellets:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a binder into a solution with the concentration of 8% by using water to serve as a binder solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. The pellets are moved into a drying room for drying, the drying condition is 30 +/-2 ℃, the drying time is 12 hours, and the dried pellets can be used as the quick-release pellets of the invention.
Example 3 preparation of immediate Release pellets
The prescription proportion is as follows:
valsartan 30 parts by weight
60 parts by weight of microcrystalline cellulose (diluent)
12 parts by weight of low-substituted hydroxypropyl cellulose (disintegrant)
And 3 parts of povidone (adhesive).
Preparation of pellets:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a binder into a solution with the concentration of 3% by using water to serve as a binder solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. The pellets are moved into a drying room for drying, the drying condition is 30 +/-2 ℃, the drying time is 12 hours, and the dried pellets can be used as the quick-release pellets of the invention.
Example 4 preparation of immediate Release pellets
The prescription proportion is as follows:
valsartan 30 parts by weight
Lactose (diluent) 80 parts by weight
20 parts by weight of crospovidone (disintegrant)
Povidone (adhesive) 4 parts by weight.
Preparation of pellets:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a 5% solution of the adhesive by using water as an adhesive solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. The pellets are moved into a drying room for drying, the drying condition is 30 +/-2 ℃, the drying time is 12 hours, and the dried pellets can be used as the quick-release pellets of the invention.
Example 5 preparation of immediate Release pellets
The prescription proportion is as follows:
valsartan 30 parts by weight
40 parts of starch/calcium hydrogen phosphate (1/2, diluent)
10 parts by weight of sodium carboxymethyl starch/croscarmellose sodium (1/1, disintegrant)
And 6 parts of povidone (adhesive).
Preparation of pellets:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a 5% solution of the adhesive by using water as an adhesive solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. The pellets are moved into a drying room for drying, the drying condition is 30 +/-2 ℃, the drying time is 12 hours, and the dried pellets can be used as the quick-release pellets of the invention.
Example 6 preparation of immediate Release pellets
The prescription proportion is as follows:
valsartan 30 parts by weight
50 parts by weight of microcrystalline cellulose/starch (1/2, diluent)
15 parts by weight of sodium carboxymethyl starch (disintegrant)
7 parts of hydroxypropyl methylcellulose (adhesive).
Preparation of pellets:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a 5% solution of the adhesive by using water as an adhesive solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. The pellets are moved into a drying room for drying, the drying condition is 30 +/-2 ℃, the drying time is 12 hours, and the dried pellets can be used as the quick-release pellets of the invention.
Example 7 preparation of immediate Release pellets
The prescription proportion is as follows:
valsartan 30 parts by weight
Dextrin (diluent) 45 weight portions
16 parts by weight of croscarmellose sodium (disintegrant)
4 parts of hydroxypropyl methylcellulose (adhesive).
Preparation of pellets:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a 5% solution of the adhesive by using water as an adhesive solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. The pellets are moved into a drying room for drying, the drying condition is 30 +/-2 ℃, the drying time is 12 hours, and the dried pellets can be used as the quick-release pellets of the invention.
Example 8 preparation of immediate Release pellets
The prescription proportion is as follows:
valsartan 30 parts by weight
40 parts by weight of starch/lactose (1/2, diluent)
5 parts by weight of croscarmellose sodium/crospovidone (2/1, disintegrant)
Povidone (adhesive) 4 parts by weight.
Preparation of pellets:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a 5% solution of the adhesive by using water as an adhesive solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. The pellets are moved into a drying room for drying, the drying condition is 30 +/-2 ℃, the drying time is 12 hours, and the dried pellets can be used as the quick-release pellets of the invention.
Example 9 preparation of immediate Release pellets
The prescription proportion is as follows:
valsartan 30 parts by weight
Dextrin/starch (2/1, diluent) 50 parts by weight
10 parts by weight of sodium carboxymethyl starch (disintegrant)
5 parts of povidone (adhesive).
Preparation of pellets:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a 5% solution of the adhesive by using water as an adhesive solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. The pellets are moved into a drying room for drying, the drying condition is 30 +/-2 ℃, the drying time is 12 hours, and the dried pellets can be used as the quick-release pellets of the invention.
The dissolution amount of each of the immediate release pellets of examples 1 to 9 is larger than 80% of the content of the main drug in the pellets and is in the range of 88 to 95% in four dissolution media at 30min, measured by dissolution test method A.
Example 10: quick release pellet coating
The pellets of examples 1-3, 4-6 and 7-9 were coated with a commercially available hydroxypropyl methylcellulose based coating pre-mix powder, Eudragit E based coating pre-mix powder, hydroxypropyl cellulose based coating pre-mix powder (all available from calcon and formulated as coating solutions according to the product specifications) respectively, using a weight of 20 parts, 15 parts and 25 parts per 30 parts by weight of active drug per each group of pellets to give 9 coated pellets. When the dissolution rate determination method A is used for determining the dissolution rate of the coated pellets, the dissolution rate of the coated pellets in four dissolution media is more than 80 percent of the content of the main drug in the pellets and is in the range of 87-95 percent at 30min, and the dissolution rates of the pellets obtained in the same example before and after coating are not obviously different (the difference of the dissolution rates is less than 1 percent). In addition, the average diameter of the coated immediate release pellets is in the range of 0.5 to 0.8 mm.
EXAMPLE 11 preparation of core for extended Release pellets
The prescription proportion is as follows:
50 parts by weight of valsartan
Dextrin (diluent) 45 weight portions
15 parts by weight of sodium carboxymethyl starch (disintegrant)
5 parts of povidone (adhesive).
Preparing a pill core:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a 4% solution of the adhesive by using water as an adhesive solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. Transferring into drying chamber, drying at 30 + -2 deg.C for 12 hr, drying to obtain pill core, and coating.
EXAMPLE 12 preparation of core for extended Release pellets
The prescription proportion is as follows:
50 parts by weight of valsartan
Microcrystalline cellulose (diluent) 30 parts by weight
15 parts by weight of low-substituted hydroxypropyl cellulose (disintegrant)
And 8 parts of hydroxypropyl methylcellulose (adhesive).
Preparing a pill core:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a binder into a solution with the concentration of 8% by using water to serve as a binder solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. Transferring into drying chamber, drying at 30 + -2 deg.C for 12 hr, drying to obtain pill core, and coating.
EXAMPLE 13 preparation of core for extended Release pellets
The prescription proportion is as follows:
50 parts by weight of valsartan
60 parts of starch (diluent)
12 parts by weight of croscarmellose sodium (disintegrant)
And 3 parts of povidone (adhesive).
Preparing a pill core:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a binder into a solution with the concentration of 3% by using water to serve as a binder solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. Transferring into drying chamber, drying at 30 + -2 deg.C for 12 hr, drying to obtain pill core, and coating.
EXAMPLE 14 preparation of core for extended Release pellets
The prescription proportion is as follows:
50 parts by weight of valsartan
Lactose (diluent) 80 parts by weight
20 parts by weight of crospovidone/sodium carboxymethyl starch (1/1, disintegrant)
Povidone (adhesive) 4 parts by weight.
Preparing a pill core:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a 5% solution of the adhesive by using water as an adhesive solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. Transferring into drying chamber, drying at 30 + -2 deg.C for 12 hr, drying to obtain pill core, and coating.
EXAMPLE 15 preparation of core for extended Release pellets
The prescription proportion is as follows:
50 parts by weight of valsartan
40 parts of starch/calcium hydrogen phosphate (2/1, diluent)
10 parts by weight of sodium carboxymethyl starch/croscarmellose sodium (1/2, disintegrant)
And 6 parts of povidone (adhesive).
Preparing a pill core:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a 5% solution of the adhesive by using water as an adhesive solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. Transferring into drying chamber, drying at 30 + -2 deg.C for 12 hr, drying to obtain pill core, and coating.
EXAMPLE 16 preparation of core for extended Release pellets
The prescription proportion is as follows:
50 parts by weight of valsartan
Microcrystalline cellulose/lactose (2/1, diluent) 50 parts by weight
15 parts by weight of crospovidone (disintegrant)
7 parts of hydroxypropyl methylcellulose (adhesive).
Preparing a pill core:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a 5% solution of the adhesive by using water as an adhesive solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. Transferring into drying chamber, drying at 30 + -2 deg.C for 12 hr, drying to obtain pill core, and coating.
EXAMPLE 17 preparation of core for extended Release pellets
The prescription proportion is as follows:
50 parts by weight of valsartan
Lactose (diluent) 45 parts by weight
16 parts by weight of croscarmellose sodium (disintegrant)
4 parts of hydroxypropyl methylcellulose (adhesive).
Preparing a pill core:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a 5% solution of the adhesive by using water as an adhesive solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. Transferring into drying chamber, drying at 30 + -2 deg.C for 12 hr, drying to obtain pill core, and coating.
EXAMPLE 18 preparation of core for extended Release pellets
The prescription proportion is as follows:
50 parts by weight of valsartan
50 parts by weight of starch/lactose (2/1, diluent)
15 parts by weight of croscarmellose sodium/crospovidone (1/2, disintegrant)
Povidone (adhesive) 4 parts by weight.
Preparing a pill core:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a 4% solution of the adhesive by using water as an adhesive solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. Transferring into drying chamber, drying at 30 + -2 deg.C for 12 hr, drying to obtain pill core, and coating.
EXAMPLE 19 preparation of core for extended Release pellets
The prescription proportion is as follows:
50 parts by weight of valsartan
Dextrin/starch (2/1, diluent) 55 parts by weight
5 parts by weight of sodium carboxymethyl starch (disintegrant)
5 parts of povidone (adhesive).
Preparing a pill core:
(1) mixing the active medicine, the diluent and the disintegrating agent uniformly according to the proportion of the prescription, crushing the mixture together to pass through a 100-mesh sieve, and mixing the mixture uniformly;
(2) preparing a 5% solution of the adhesive by using water as an adhesive solution;
(3) preparing the mixed powder in the step (1) into a soft material by using a binder solution, preparing the pellets by adopting an extrusion-spheronization pill forming method, extruding the mixed wet material into strips at an extrusion speed of 10-40r/min, moving the strips into a spheronization device, cutting the extrudate at a rotating speed of 40-70Hz, and spheronizing the strips at a rotating speed of 30-50Hz for 10-20 minutes to prepare the pellets. Transferring into drying chamber, drying at 30 + -2 deg.C for 12 hr, drying to obtain pill core, and coating.
The pellet cores of examples 11 to 19 were dissolved out in four kinds of dissolution media at 30min in a range of 87 to 96% in each of which the amount of dissolution was more than 85% of the content of the main drug in the pellet, as measured by dissolution test method A.
Example 20: delayed release pellet coating
Nine pellets of examples 11 to 19 were coated with each other by using 9 kinds of commercially available cellulose acetate phthalate based coating pre-mixed powder, hypromellose phthalate based coating pre-mixed powder, polyvinyl alcohol phthalate based coating pre-mixed powder, Eudragit L based coating pre-mixed powder, Eudragit S based coating pre-mixed powder, acrylic resin I based coating pre-mixed powder, acrylic resin II based coating pre-mixed powder, acrylic resin IV based coating pre-mixed powder, methacrylic acid copolymer based coating pre-mixed powder (all available from kallikang corporation and formulated into coating solutions according to the product specifications), the coating layer was used in each pellet in the amounts of 20 parts by weight (examples 11-13), 15 parts by weight (examples 14-16), and 25 parts by weight (examples 17-19), respectively, per 50 parts by weight of the active drug, to give 9 coated pellets. The formulation of these coating materials, for example, methacrylic acid copolymer-based coating premix powders, is: 200 parts of methacrylic acid copolymer, 20 parts of triethyl citrate, 40 parts of talcum powder and 1740 parts of water for preparation when in use; for another example, the formula of the acrylic resin II-based coating premixed powder is as follows: 300 parts of acrylic resin II, 20 parts of hydroxypropyl methyl fiber, 50 parts of titanium dioxide, 75 parts of zein, 40 parts of polyethylene glycol and 15 parts of glycerol, and 500 parts of water is added for preparation when in use.
In the context of the present invention, the process conditions used when carrying out the various coating processes are: a Glatt fluidized bed coating machine is used, the airflow temperature is 55 ℃, the pellet temperature is 32 ℃, the atomization pressure is 0.25-0.30MPa, the guniting speed is 150mL/min, and the coating weight gain control is determined according to the prescription.
The coated pellets have an average diameter in the range of 0.5 to 0.8 mm.
The coated pellets were subjected to a dissolution test A, and when the pellets were dissolved in four dissolution media, appropriate amounts of the solutions were taken at1 hour, 2 hours, 3 hours, and 4 hours, respectively, to measure the amount of dissolution in each dissolution medium at that time point, and as a result: the dissolution amount in two dissolution media of pH1.2 and pH4.0 at 4 hours is less than 10% of the content of the main drug in the pellet and is in the range of 2-5%; the dissolution amount in two dissolution media of pH6.8 and water at1 hour reaches the range of 85-91% of the content of the main drug in the pellet; the dissolution amount in two dissolution media of pH6.8 and water at2 hours is more than 93 percent of the content of the main drug in the pellet.
This indicates that these pellets exhibited different release patterns before and after coating, with essentially no release at low pH, but a significant portion already released in neutral medium before 1 hour, which release pattern was not in compliance with the design requirements for controlling morning waking hypertension; although this release pattern is consistent with the release expectations of typical enteric formulations.
In addition, one of these coated delayed release pellets obtained in example 20 was mixed with any of the coated immediate release pellets obtained in example 10 (in an active ingredient ratio of 50: 30) and filled in empty capsules, each containing 80mg of the active ingredient. The pharmaceutical composition of capsules containing two kinds of pellets was measured by dissolution test method a, and when the composition was dissolved in four dissolution media, appropriate amounts of solutions were taken at 0.5 hour, 1 hour, 2 hours, 3 hours, and 4 hours, respectively, to measure the amount of dissolution in each dissolution medium at that time point, and as a result: the amount eluted at 0.5 hours in both dissolution media pH1.2 and pH4.0 is 90-120% (e.g. 90-110%) of the amount of drug in the first release phase portion of the pharmaceutical composition; the amount eluted at 4 hours in both dissolution media pH1.2 and pH4.0 is 100-140% (e.g., 100-125%) of the amount of drug in the first release phase portion of the pharmaceutical composition; the dissolution amount in two dissolution media of pH6.8 and water at1 hour reaches 91-95% of the content of the main drug in the capsule; the dissolution amount in two dissolution media of pH6.8 and water at2 hr is more than 96% of the content of the main drug in the capsule. These results indicate that it is difficult to achieve a drug release pattern with two release times before 1 and 5 hours after the two pellet combinations were taken around 9 nights.
Example 21: delayed release pellet coating
Nine pellets of examples 11 to 19 were subjected to delayed-release pellet coating in accordance with the procedure of example 20 above, except that 2% (percent by weight with respect to the weight of the coating material) of a coating aid was additionally added to the coating solution to obtain 9 kinds of coated pellets.
The coated pellets were subjected to a dissolution test A, and when the pellets were dissolved in four dissolution media, appropriate amounts of the solutions were taken at2 hours, 3 hours, and 4 hours, respectively, to measure the amount of dissolution in each dissolution medium at that time point, and as a result: the dissolution amount in two dissolution media of pH1.2 and pH4.0 at 4 hours is less than 10% of the content of the main drug in the pellet and is in the range of 3-6%; the dissolution amount in two dissolution media of pH6.8 and water at2 hours is less than 15 percent of the content of the main drug in the pellet and is in the range of 6 to 11 percent; the dissolution amount in two dissolution media of pH6.8 and water at 3 hours is more than 80 percent of the content of the main drug in the pellet, and the dissolution amounts are both in the range of 88 to 94 percent. These results show thatDelayed release coated pellet obtained in example 21The delayed release pattern in intestinal fluid environment meets the design requirements for controlling morning blood pressure, and the delayed release pattern in intestinal fluid environment can meet the design requirements of controlling morning blood pressure.
Example 22: preparation of hard capsules with biphasic Release Properties
The delayed release coated pellets (pellets as the second release phase portion) obtained in example 21 above were mixed with the various immediate release coated pellets (pellets as the first release phase portion) obtained in example 10 in the ratio of 7:3, 7:4, 7:5, 5:3, 5:4, 7:5, respectively, by weight of the active ingredient, and the resulting mixed pellets were filled into hard capsules each containing 80mg of valsartan, to obtain hard capsules having a biphasic release property. These hard capsules were measured by the dissolution test method A, and when they were dissolved in four dissolution media, appropriate amounts of the solutions were taken at 0.5 hour, 2 hours, 3 hours, and 4 hours, respectively, to measure the amount of dissolution in each dissolution medium at that time point, and as a result:
the dissolution amount of all capsules in two dissolution media of pH1.2 and pH4.0 at 0.5 hour is 93-109% of the drug amount of the first release phase in the hard capsule drug composition; the dissolution amount in two dissolution media of pH1.2 and pH4.0 at 4 hr is 103-121% of the medicine amount of the first release phase part in the hard capsule pharmaceutical composition; the dissolution amount in two dissolution media of pH6.8 and water at2 hours is 107-129% of the medicine amount of the first release phase part in the hard capsule medicine composition; the dissolution amount in two dissolution media of pH6.8 and water at 3 hours is more than 85% (both are in the range of 94-97%) of the traditional Chinese medicine amount of the hard capsule pharmaceutical composition.
The above results show that the resulting sustained release coated pellets and the resulting dual phase release hard capsule formulation exhibit the dual phase release performance as in the present invention typically spaced about 5 hours apart only when a trace amount of coating aid is added to the second release phase partial coating solution.
Example 23: preparation of hard capsules with biphasic Release Properties
With reference to the prescription and method of example 10 above, respectively, the active ingredient was changed to amlodipine besylate to give immediate release pellets having the properties of the first release phase portion; the active ingredient was changed to amlodipine besylate to give extended release pellets having the properties of the second release phase portion with reference to the formulation and method of example 21 above, respectively. The two types of pellets were tested according to dissolution test a and the results showed that their release patterns were substantially identical to the pellets described in example 10 and example 21, respectively. The above two amlodipine besylate pellets were used to prepare hard capsules having biphasic release property in the same manner as in example 22, each capsule containing 5mg of amlodipine besylate, to obtain hard capsules having biphasic release property. These hard capsules were tested according to dissolution test A and showed a release pattern substantially identical to that of the hard capsules described in example 22, namely: the drug of the first release phase part is mainly released within 4 hours in an acidic medium, the drug of the first release phase part is mainly released within 2 hours in a neutral medium, and the drug of the first release phase part and the drug of the second release phase part are basically and completely released at 3 hours in the neutral medium.
Example 24: preparation of hard capsules with biphasic Release Properties
With reference to the prescription and method of example 10 above, respectively, the active ingredient was changed to captopril, resulting in immediate release pellets having the properties of a first release phase portion; the active ingredient was changed to captopril to give extended release pellets having the properties of the second release phase portion, with reference to the formulation and method of example 21 above, respectively. The two types of pellets were tested according to dissolution test a and the results showed that their release patterns were substantially identical to the pellets described in example 10 and example 21, respectively. Hard capsules having biphasic release properties were prepared from the above two captopril pellets in the same manner as in example 22, each capsule containing 50mg of captopril to give hard capsules having biphasic release properties. These hard capsules were tested according to dissolution test A and showed a release pattern substantially identical to that of the hard capsules described in example 22, namely: the drug of the first release phase part is mainly released within 4 hours in an acidic medium, the drug of the first release phase part is mainly released within 2 hours in a neutral medium, and the drug of the first release phase part and the drug of the second release phase part are basically and completely released at 3 hours in the neutral medium.
Claims (10)
1. A pharmaceutical composition for timed release drug therapy of hypertension, the pharmaceutical composition being in the form of pellets comprising a first release phase section and a second release phase section; wherein,
the pellets of the first release phase portion comprise: an active drug, a diluent, a disintegrant, a binder, and optionally a coating layer;
the pellets of the second release phase portion comprise: active drug, diluent, disintegrating agent, adhesive and coating layer for regulating drug release.
2. The pharmaceutical composition according to claim 1, wherein the active drug is a blood pressure lowering drug; for example, a hypotensive agent selected from the group consisting of: valsartan, amlodipine and pharmaceutically acceptable salts thereof such as maleate, besylate, aspartate, mesylate, captopril and the like.
3. The pharmaceutical composition according to claim 1, wherein the active drug in the first release phase portion comprises 30% to 50% of the total amount of active drug in the pharmaceutical composition, and the active drug in the second release phase portion comprises 50% to 70% of the total amount of active drug in the pharmaceutical composition.
4. The pharmaceutical composition according to claim 1, wherein:
the diluent in the first release phase portion is selected from: microcrystalline cellulose, starch, dextrin, lactose, dibasic calcium phosphate, and combinations thereof;
the diluent in the first release phase part is present in an amount of 30 to 80 parts by weight, for example 30 to 60 parts by weight, per 30 parts by weight of the active drug;
the disintegrant in the first release phase portion is selected from: crospovidone, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, croscarmellose sodium, and combinations thereof;
the disintegrant is present in the first release phase portion in an amount of 5 to 30 parts by weight, for example 10 to 20 parts by weight, per 30 parts by weight of active drug;
the binder in the first release phase portion is selected from: povidone, methylcellulose, ethylcellulose, carboxymethylcellulose, starch slurry, hypromellose, gelatin, polyethylene glycol, sodium alginate, water, ethanol, and combinations thereof;
the binder is present in the first release phase portion in an amount of 2 to 10 parts by weight, for example 3 to 8 parts by weight, per 30 parts by weight of active drug;
the coating layer of the first release phase part is a coating layer which can be dissolved in the gastric acid environment; examples of specific coating materials such as Eudragit E, Hydroxypropylmethylcellulose (HPMC), Hydroxypropylcellulose (HPC), and the like;
the weight of the coating layer in the first release phase part is 10 to 30 parts by weight, for example 15 to 25 parts by weight, per 30 parts by weight of the active drug;
the pellets of the first release phase fraction have an average diameter of 0.2 to 2mm, such as 0.5 to 1.5mm, such as 0.5 to 1.2mm, such as 0.5 to 0.8 mm; and/or
The pellets of the first release phase fraction were tested in the following dissolution test method a, which at 30min gave dissolution in four dissolution media of more than 80% of the content of the main drug in the pellets, the operation of which was as follows: filling an appropriate amount of pellets corresponding to 50mg of an active drug (such as valsartan) into an empty capsule, respectively using a pH1.2 hydrochloric acid solution, a pH4.0 phosphate buffer (6.80 g of potassium dihydrogen phosphate is taken and dissolved in water to 1000mL, and the pH value is adjusted to 4.0 by phosphoric acid or sodium hydroxide) and a pH6.8 phosphate buffer (6.80 g of potassium dihydrogen phosphate and 0.90g of sodium hydroxide are taken and dissolved in water to 1000mL, the pH value is adjusted to 6.8), 1000mL of water is taken as a dissolution medium, the rotating speed is 100 revolutions per minute, operating according to the method, taking an appropriate amount of the solution at a specified time point, filtering, precisely taking an appropriate amount of a subsequent filtrate, quantitatively diluting the subsequent filtrate with the dissolution medium to prepare a solution containing about 16 mu g of the active drug in each 1mL, and measuring absorbance at a wavelength of 250nm according to an ultraviolet-visible spectrophotometry according to the first method of the general rule of the national regulation of "Chinese pharmacopoeia" 2015 edition; taking another appropriate amount of active drug reference substance, precisely weighing, adding dissolution medium to dissolve and quantitatively diluting to obtain solution containing 16 μ g per 1ml, measuring by the same method, and calculating dissolution amount of each capsule in different dissolution media.
5. The pharmaceutical composition according to claim 1, wherein
The diluent in the second release phase portion is selected from: microcrystalline cellulose, starch, dextrin, lactose, dibasic calcium phosphate, and combinations thereof;
the diluent in the second release phase part is present in an amount of 30 to 80 parts by weight, for example 30 to 60 parts by weight, per 50 parts by weight of the active drug;
the disintegrant in the first release phase portion is selected from: crospovidone, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, croscarmellose sodium, and combinations thereof;
the disintegrant is present in the second release phase portion in an amount of 5 to 30 parts by weight, for example 10 to 20 parts by weight, per 50 parts by weight of active drug;
the binder in the second release phase portion is selected from: povidone, methylcellulose, ethylcellulose, carboxymethylcellulose, starch slurry, hypromellose, gelatin, polyethylene glycol, sodium alginate, water, ethanol, and combinations thereof;
the binder is present in the second release phase portion in an amount of 2 to 10 parts by weight, for example 3 to 8 parts by weight, per 50 parts by weight of active drug;
the coating layer of the second release phase part is a coating layer which cannot be dissolved in the gastric acid environment; for example, the coating material used for the coating layer is a gastric-soluble type coating material; examples of typical coating materials are, for example, cellulose acetate phthalate, hypromellose phthalate (HPMCP), polyvinyl alcohol phthalate (PVAP), Eudragit L, Eudragit S, acrylic resin I, acrylic resin II, acrylic resin IV, methacrylic acid copolymer, and the like; and/or
The weight of the coating layer in the second release phase part is 20 to 50 parts by weight, for example 20 to 40 parts by weight, per 50 parts by weight of the active drug.
6. The pharmaceutical composition according to claim 1, wherein the pellets of the second release phase fraction have an average diameter of 0.2 to 2mm, such as 0.5 to 1.5mm, such as 0.5 to 1.2mm, such as 0.5 to 0.8 mm.
7. The pharmaceutical composition according to claim 1, wherein the pellets of the second release phase fraction are taken in appropriate amounts at2 hours, 3 hours, 4 hours respectively upon dissolution in four dissolution media as determined by dissolution method a, the amount of dissolution at that time point in each dissolution media being determined wherein:
the dissolution amount in two dissolution media of pH1.2 and pH4.0 at 4 hr is less than 10% of the main drug content in the pellet;
the dissolution amount in two dissolution media of pH6.8 and water at2 hours is less than 15% of the content of the main drug in the pellet;
the dissolution amount in two dissolution media of pH6.8 and water at 3 hours is more than 80% of the content of the main drug in the pellet.
8. The pharmaceutical composition according to claim 1, wherein the amount of dissolution in each dissolution medium at that time point is determined by taking appropriate amounts of solution at 0.5 hour, 2 hours, 3 hours, 4 hours, respectively, upon dissolution in four dissolution media, as determined by dissolution assay a, wherein:
the amount eluted at 0.5 hours in both dissolution media pH1.2 and pH4.0 is 90-120% (e.g. 90-110%) of the amount of drug in the first release phase portion of the pharmaceutical composition;
the amount eluted at 4 hours in both dissolution media pH1.2 and pH4.0 is 100-140% (e.g., 100-125%) of the amount of drug in the first release phase portion of the pharmaceutical composition;
the amount eluted at2 hours in both dissolution media pH6.8 and water is 100-140% (e.g. 100-130%) of the amount of drug in the first release phase portion of the pharmaceutical composition;
the amount of the extract in the two dissolution media of pH6.8 and water at 3 hr is more than 85% (such as more than 90%) of the amount of the Chinese medicinal materials in the pharmaceutical composition.
9. The pharmaceutical composition according to any of claims 1 to 8, wherein the pellets of the first release phase portion and the pellets of the second release phase portion are each independently prepared according to a process comprising the steps of:
(1) adding the diluent and the disintegrant into the active medicine, uniformly mixing and crushing;
(2) preparing an adhesive solution with the concentration of 3-5% by using water, and preparing a soft material from the obtained material in the previous step;
(3) preparing pellets by extrusion-spheronization pelleting method or centrifugation-fluidization pelleting method, and drying to obtain pellet cores;
(4) coating the pellets of the second release phase fraction obtained in step (3), optionally with a coating of the pellets of the first release phase fraction;
(5) mixing the two pellets at a certain ratio, and filling into hollow capsule to obtain the pharmaceutical composition in the form of hard capsule preparation.
10. Use of a pharmaceutical composition according to any one of claims 1 to 9 in the manufacture of a medicament for the timed release of a drug for the treatment of hypertension; for example, the timed release drug treatment of hypertension is to administer a therapeutically effective amount of the pharmaceutical composition to a hypertensive patient in need thereof at night just before bedtime.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710664741.3A CN107213138B (en) | 2017-08-07 | 2017-08-07 | Method and pharmaceutical composition for treating hypertension by timed release of drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710664741.3A CN107213138B (en) | 2017-08-07 | 2017-08-07 | Method and pharmaceutical composition for treating hypertension by timed release of drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107213138A true CN107213138A (en) | 2017-09-29 |
| CN107213138B CN107213138B (en) | 2020-12-18 |
Family
ID=59954617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710664741.3A Active CN107213138B (en) | 2017-08-07 | 2017-08-07 | Method and pharmaceutical composition for treating hypertension by timed release of drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107213138B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114129541A (en) * | 2022-01-05 | 2022-03-04 | 南通联亚药业有限公司 | Diltiazem hydrochloride sustained-release capsule and preparation method and application thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
| WO1997033569A1 (en) * | 1996-03-13 | 1997-09-18 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Medicament preparation for angiotensin converting enzyme (ace)-inhibitors |
| CN101132782A (en) * | 2005-02-21 | 2008-02-27 | 弗拉梅技术公司 | Orally tanken medicament preparation of losartan |
| CN101229132A (en) * | 2008-02-03 | 2008-07-30 | 济南宏瑞创博医药科技开发有限公司 | Nimodipine pulse sustained release mircopill preparation and preparing method thereof |
| CN101249083A (en) * | 2008-03-21 | 2008-08-27 | 北京润德康医药技术有限公司 | Compound extended release formulation containing amlodipine and metoprolol and preparation |
| CN101534798A (en) * | 2006-10-30 | 2009-09-16 | 韩兀制药株式会社 | Controlled release pharmaceutical composition containing thiazides and angiotensin-II-receptor blockers |
| CN102600451A (en) * | 2012-01-17 | 2012-07-25 | 广州科的信医药技术有限公司 | Felodipine ramipril compound sustained-release preparation and preparation method thereof |
| CN103222960A (en) * | 2013-05-15 | 2013-07-31 | 中国药科大学 | Oral enalapril maleate timed-release pellet and preparation method thereof |
| US20150079170A1 (en) * | 2007-05-30 | 2015-03-19 | Girish Kumar Jain | Novel tablet dosage form |
-
2017
- 2017-08-07 CN CN201710664741.3A patent/CN107213138B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
| WO1997033569A1 (en) * | 1996-03-13 | 1997-09-18 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Medicament preparation for angiotensin converting enzyme (ace)-inhibitors |
| CN101132782A (en) * | 2005-02-21 | 2008-02-27 | 弗拉梅技术公司 | Orally tanken medicament preparation of losartan |
| CN101534798A (en) * | 2006-10-30 | 2009-09-16 | 韩兀制药株式会社 | Controlled release pharmaceutical composition containing thiazides and angiotensin-II-receptor blockers |
| US20150079170A1 (en) * | 2007-05-30 | 2015-03-19 | Girish Kumar Jain | Novel tablet dosage form |
| CN101229132A (en) * | 2008-02-03 | 2008-07-30 | 济南宏瑞创博医药科技开发有限公司 | Nimodipine pulse sustained release mircopill preparation and preparing method thereof |
| CN101249083A (en) * | 2008-03-21 | 2008-08-27 | 北京润德康医药技术有限公司 | Compound extended release formulation containing amlodipine and metoprolol and preparation |
| CN102600451A (en) * | 2012-01-17 | 2012-07-25 | 广州科的信医药技术有限公司 | Felodipine ramipril compound sustained-release preparation and preparation method thereof |
| CN103222960A (en) * | 2013-05-15 | 2013-07-31 | 中国药科大学 | Oral enalapril maleate timed-release pellet and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 杨梅等: "替米沙坦联合苯磺酸氨氯地平治疗晨峰高血压疗效观察", 《现代医药卫生》 * |
| 沈淑媛等: "复方美托洛尔- 氨氯地平双层片体外释放度方法研究", 《制剂与技术》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114129541A (en) * | 2022-01-05 | 2022-03-04 | 南通联亚药业有限公司 | Diltiazem hydrochloride sustained-release capsule and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107213138B (en) | 2020-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI484957B (en) | Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin ii antagonist and/or a diuretic | |
| KR101207618B1 (en) | Pharmaceutical formulation for treating cardiovascular disease | |
| DK2830618T3 (en) | A pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
| KR101238156B1 (en) | Pharmaceutical formulation | |
| JP2003503341A (en) | Pharmaceutical dosage forms for controlled release producing at least one timely pulse | |
| JP2002542208A (en) | Oral formulation for ileal administration containing ileal bile acid transport inhibitor compound | |
| JP2010505943A (en) | Combination preparation for treatment of cardiovascular disease based on chronotherapy theory | |
| US20110172210A1 (en) | Method for titrating clozapine | |
| JP2003510346A (en) | New pharmaceutical composition | |
| JPH01313427A (en) | Gradual release preparation containing dihydropyridines | |
| WO2013123413A2 (en) | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof | |
| US20050032879A1 (en) | Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases | |
| CN107213138B (en) | Method and pharmaceutical composition for treating hypertension by timed release of drugs | |
| CN102247366A (en) | Medicinal composition comprising quick-release pellets containing Enalapril or Enalapril-acid addition salt and slow-release pellets containing Felodipine | |
| US20060165788A1 (en) | Lercanidipine pH dependent pulsatile release compositions | |
| KR101990951B1 (en) | A sustained releasing Pharmaceutical Composition comprising Rivastigmine | |
| EP2883546B1 (en) | New differential-release pharmaceutical composition containing three active principles | |
| KR20110129405A (en) | Pharmaceutical preparation | |
| KR20090107959A (en) | Pharmaceutical formulation | |
| US11759471B2 (en) | Modified release pharmaceutical composition and method for the treatment of mental disorders | |
| WO2024109927A1 (en) | Pharmaceutical composition comprising azilsartan medoxomil potassium and calcium channel blocker, method for preparing same, and use thereof | |
| CN117298112A (en) | Pharmaceutical composition comprising quinoline derivative or salt thereof and preparation method thereof | |
| KR20090107960A (en) | Pharmaceutical formulation for treating cardiovascular disease | |
| WO2009134053A2 (en) | Pharmaceutical composition containing thiazide-based compound with controlled release and angiotensin-ii-receptor blocker | |
| CN109674794A (en) | A kind of Amlodipine benazepil pulsatile tablets and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |